Bracco has received Health Canada approval for Vueway® (gadopiclenol) injection, expanding access to a next-generation magnetic resonance imaging (MRI) contrast agent designed to deliver high diagnostic performance at a lower dose.

Vueway is a macrocyclic gadolinium-based contrast agent (GBCA) developed to enhance MRI imaging while reducing total gadolinium exposure. Unlike conventional contrast agents, gadopiclenol achieves comparable image quality at approximately half the gadolinium dose, addressing long-standing safety concerns associated with cumulative gadolinium retention.

The approval marks an important step in advancing contrast-enhanced imaging, particularly in patient populations where minimizing exposure is critical. MRI contrast agents are widely used to improve visualization of lesions and abnormalities across the central nervous system and other body regions, enabling more accurate diagnosis and disease monitoring.

Vueway’s high relaxivity allows it to produce strong signal enhancement even at reduced doses, supporting diagnostic confidence without compromising image clarity. This is particularly relevant in repeat imaging scenarios and vulnerable patient groups, where cumulative exposure to contrast agents is a key consideration.

The product has already been approved in multiple regions, including the United States and European Union, and is now expanding into additional markets such as Canada. This broader regulatory momentum reflects increasing demand for safer and more efficient imaging solutions.